

## Biographical sketch CIRO ISIDORO



**Nome** CIRO ISIDORO

**Email** ciro.isidoro@med.uniupo.it

**Professore Ordinario** di Patologia Generale e Patologia Clinica

**Qualifica ASN di Professore Ordinario di**

Biochimica Clinica e Biologia Molecolare Clinica

Oncologia Medica

**Affiliazione** Università del Piemonte Orientale, Dipartimento di Scienze della Salute; via Paolo Solaroli 17 – 28100, Novara (Italy)

**Website:** <http://www.isidorolab.com/> <https://upobook.uniupo.it/ciro.isidoro@med>

### Titoli Accademici:

1983 – Laurea *Summa cum Laude* – Dottore magistrale in Scienze Biologiche (Doctor of Science), Università di Torino (Italia)

1984 – Abilitazione Nazionale alla professione di Biologo

1999 - Laurea *Summa cum Laude* – Dottore in Medicina e Chirurgia (M.D.), Università del Piemonte Orientale (Novara, Italia)

2000 – Abilitazione Nazionale alla professione di Medico-Chirurgo; iscritto all’Albo dei Medici-Chirurghi e Odontoiatri della provincia di Torino (n. 19820).

### Posizioni Accademiche rappresentative:

**2023: TOP 2% Scientist in the world based on scientific production in 2022.**

1983-1986: post-doc borsista presso Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Torino, Italia)

1986-1989: PhD fellow-Assistant Researcher (Rerum Medicinalis) = dottorando in Scienze Mediche presso Institut fuer Pathobiochemie, Westfaelish-Wilhems Universitaet Muenster (Germany); assistente di ricerca (Wissenschaftliche Hilfskraft) dal 15.02.1989 fino al 31.03.1990.

1989-1992: Post-doc-Professore a Contratto presso Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italia)

**1993-1999: Ricercatore confermato (Assistant Professor) di Patologia Generale, Università di Torino (Italia)**

**2000 to 2019: Professore Associato di Patologia Cellulare e Oncologia Sperimentale, Scuola di Medicina, Università del Piemonte Orientale (Novara, Italia).**

2000-2000: Visiting Professor at Institute fuer Physiologische Chemie (Prof. A. Hasilik), Klinikum der Philipps-Universitaet Marburg (D)

2002-2005: Visiting Professor at Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol (UK).

2005 to date: overseas advisor of PhD students at Mahidol University, at Chulalongkorn University, Bangkok; at Khon Kaen University (Thailand)

2013-2020: Visiting Professor, Siriraj Faculty of Medicine, Mahidol University of Bangkok (Thailand).

## Biographical sketch CIRO ISIDORO

2016 to present: Visiting Professor, Department of Cell Biology, Oklahoma University Health Science Center (OKC, U S).

2018 to 2019: Visiting Professor, Faculty of Allied Health Sciences, Chulalongkorn University of Bangkok (Thailand).

2019-2020: Visiting Professor, University of Bourgogne France-Comté, Besancon (France)

**2019 - oggi: Professore Ordinario di Patologia Generale, Patologia Cellulare e Oncologia Sperimentale, Scuola di Medicina, Università del Piemonte Orientale (Novara, Italia).**

2019-2020 Adjunct Professor Dept of Medicine, College of Medicine, Seoul National University, Seoul (South Korea)

2019-2020: Adjunct Professor Medical Research Institute, Tokyo Medical and Dental University, Tokyo (Japan) 2020-

present: Adjunct Professor Siriraj Hospital-Faculty of Medicine, Mahidol University, Bangkok (Thailand)

### Premi e Riconoscimenti Internazionali:

**2023: TOP 2% Best Scientists in the World among 8.5 million**

**2023: TOP Italian Scientist in Scienze Biomediche**

**2023: listed as Best Scientist in Biochimica**

**2014: Professor Honoris Causa Faculty of Medicine and Pharmacy, Université de Bourgogne & Franche-Comté of Besançon (France).**

**2015:** member of the Scientific board of « Integrative Cancer Research Center of the Georgia Institute of Technology », Georgia Tech University, Georgia (Atlanta, US) <https://icrc.gatech.edu/people/Ciro-Isidoro>; <https://icrc.gatech.edu/user/299>

**2015:** Executive Vice-President of the International Association of Traditional and Complementary Medicine.

**2018:** Full member of the World Academy of Sciences <http://www.worldacademyofsciences.com/members.html>

### EDITORIAL BOARD

**Editor-in-Chief** of J of Cancer and Metastasis Treatment (2024 to date; <https://www.oaepublish.com/jcmt/editor>); J of Gene and Cell Metabolism in Medicine (2026; <https://jgcmmed.com/jgcmmed>), J Traditional and Complementary Medicine (2014-2024); Biomedicines (Advisor board member)

**Associate Editor** of Autophagy, J Translational Medicine, Cancers, Cells, Int J Molecul. Sci, Molecular Carcinogenesis, Frontiers in Oncology, Oncology Lett, Oncology Res, Exptl. & Therap. Medicine, (others)

**Aree di Ricerca:** Ruolo e regolazione dell'autofagia nel cancro e nella neurodegenerazione. Regolazione epigenetica dell'autofagia e della morte cellulare. Nutraceutici anti-invecchiamento e anti-tumorali. Biogenesi degli organelli, traffico vescicolare e malattie. Nanoteranostici (imaging "in cellulo"). Tecnologie omiche nella diagnosi e terapia delle malattie umane. Meccanismi molecolari e fisiopatologici della COVID-19 e degli effetti avversi del vaccino COVID-19.

**Brevetti: International Patent** (C. Follo e C. Isidoro), PCT No. WO2008/065505 (5-06-2008).

LINK: <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2008065505&redirectedID=true>

### Bibliometric index:

Scopus H Index = 56; citazioni >10.000

Google Scholar H Index = 59; citazioni >25.000

Google Scholar personal webpage <https://scholar.google.it/citations?hl=it&user=YaKkwGMAAAAJ>

Total Impact Factor >1250

**ORCID** <https://orcid.org/0000-0002-5494-3034>

**Publications** 202 full articles in peer-review journals plus 16 chapters/books.

## Biographical sketch CIRO ISIDORO

PUBMED <https://www.ncbi.nlm.nih.gov/pubmed/?term=isidoro+c>

### **INTERNATIONAL SCIENTIFIC SOCIETY MEMBERSHIP**

- International Society of Precision Cancer Medicine (founder member, since Apr 2018)
- International Association of Traditional and Complementary Medicine (Executive Vice President, since Nov 2015)
- International Proteolysis Society (founder member, since 1999)
- Associazione Italiana di Biologia Cellulare e del Differenziamento (ABCD) (founder member)
- Italian Society of Cancerology
- European Cancer Society
- European Cell Biology Society


### **TOP 2% Scientist in the world based on quality of scientific production in 2022.**

**Prof. Ciro Isidoro ranks 157259 among 8.5 million scientists in the world.**

A bibliometric study performed by the Prof. J. Ioannidis's team at Stanford University has considered the quantity, quality, and diffusion of publications within the scientific community and elaborated standardized information on citations, h-index, co-authorship adjusted hm-index, citations to papers in different authorship positions and a composite indicator (c-score). The authors analyzed data relating to over 8 and a half million researchers from universities and research centers throughout the world. Among them, approximately **195,000 scientists stood out for their scientific authority and currently represent the best 2%. In this ranking, Prof. Ciro Isidoro is n. 157259.**

<https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6>

[https://drive.google.com/file/d/1ro19angG6WqVA5zX9vUISegw38QLQok0/view?usp=drive\\_web](https://drive.google.com/file/d/1ro19angG6WqVA5zX9vUISegw38QLQok0/view?usp=drive_web)




<https://exaly.com/author/5026208/ciro-isidoro/h-index>

## Biographical sketch CIRO ISIDORO

### Best Biology and Biochemistry Scientists

The 2nd edition of Research.com ranking of the best scientists in the field of Biology and Biochemistry relies on data derived from a wide range of data sources including OpenAlex and CrossRef. The bibliometric data for devising the citation-based metrics were acquired on 21-12-2022. Position in the ranking is based on a scholar's D-index (Discipline H-index), which takes into account only publications and citation values for an examined discipline.


[Show more](#)

World	National	Scholar	D-index	Citations	Publications
12866	386	 <b>Ciro Isidoro</b> University of Eastern Piedmont Amadeo Avogadro, Italy	50	32,485	170

The 2023 Edition of our Ranking of Top Scientists in the field of Biology and Biochemistry released recently at <https://research.com/scientists-rankings/biology-and-biochemistry>

### TOP ITALIAN SCIENTIST IN BIOMEDICAL SCIENCES

<https://topitalianscientists.org/top-italian-scientists-scopus/Biomedical%20Sciences/1>



Top Italian Scientists							Select a Macroarea	
Biomedical Sciences							1-100 101-200 201-300 301-400 401-500 501-600 601-700 701-800 801-900 901-1000 1001-1100 1101-1200 1201-1300 1301-1400 1401-1500 1501-1600 1601-1700 1701-1800	
1329	Ciro Isidoro	48	19,885	Italy	cancer - medicine	Biomedical Sciences	Università degli Studi del Piemonte Orientale "Amedeo Avogadro"	<a href="#">Google Scholar</a> <a href="#">MyCitations</a>

**CODICE FISCALE** SDRCRI56M29Z326U;

"Ai sensi del GDPR (2016/679) e della normativa vigente in materia di privacy autorizzo il trattamento dei miei dati personali. Dichiaro, inoltre, che ogni informazione espressa nel presente Curriculum Vitae corrisponde a verità".

**Autorizzo e consento il trattamento dei miei dati personali ai sensi dell'art. 13 del D.Lgs. 196/03 e dell'art. 13 GDPR 679/16 e Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".**

**Novara, 25 giugno 2026**

## Biographical sketch CIRO ISIDORO

### PUBBLICAZIONI RECENTI (2024-2026)

202. Thongchot S, Kittirat Y, Promraksa B, Ferraresi A, Vidoni C, Loilome W, Namwat N, Isidoro C. Preclinical demonstration of the efficacy and mechanisms of antitumor activity of dihydroartemisinin in cholangiocarcinoma xenograft: Induction of autophagy and reprogramming of metabolism. *Biomed Pharmacother.* 2026 Apr 27;199:119438. doi: 10.1016/j.biopha.2026.119438. Epub ahead of print. PMID: 42048718.
201. Isidoro C, Song YS, Dhanasekaran DN. Closing the Loop: A Dynamic "Sample-to-Answer" Ecosystem for Vascularized Tumor Modeling and Real-Time Therapies. *Cancer Lett.* 2026 Feb 11:218302. doi: 10.1016/j.canlet.2026.218302. Epub ahead of print. PMID: 41687769.
200. Munteanu C, Nadhan R, Turti S, Prifti E, Achim L, Basu S, Ferraresi A, Ha JH, Isidoro C, Dhanasekaran DN. LncRNAs at the Crossroads of Precision Nutrition and Cancer Chemoprevention. *Cancers (Basel).* 2026 Jan 29;18(3):430. doi: 10.3390/cancers18030430. PMID: 41681904; PMCID: PMC12897057.
199. Isidoro, C. SARS-CoV2 and Anti-COVID-19 mRNA Vaccines: Is There a Plausible Mechanistic Link with Cancer? *Cancers* 2025, 17, 3867. <https://doi.org/10.3390/cancers17233867>
198. Nadhan R, Nath K, Basu S, Isidoro C, Song YS, Dhanasekaran DN. Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks. *Signal Transduct Target Ther.* 2025 Oct 10;10(1):337. doi: 10.1038/s41392-025-02423-4. PMID: 41068071; PMCID: PMC12511386.
197. Garavaglia B, Ferraresi A, Vidoni C, Vallino L, Lualdi C, Mollace V, Isidoro C. Butyrate and Resveratrol synergize to inhibit colorectal cancer cell proliferation and migration by preventing the nuclear translocation of  $\beta$ -catenin. *BIO Web of Conferences* 187, 04001 (2025) ISPH-ISNPR 2025, <https://doi.org/10.1051/bioconf/202518704001>
196. Maheshwari, C.; Castiglioni, A.; Walusimbi, U.; Vidoni, C.; Ferraresi, A.; Dhanasekaran, D.N.; Isidoro, C. The Biological Role and Clinical Significance of BECLIN-1 in Cancer. *Int. J. Mol. Sci.* 2025, 26, 9380. <https://doi.org/10.3390/ijms26199380>
195. Garavaglia B, Vallino L, Ferraresi A, Visciglia A, Amoruso A, Pane M, Munteanu C, Isidoro C. The Anti-Inflammatory, Immunomodulatory, and Pro-Autophagy Activities of Probiotics for Colorectal Cancer Prevention and Treatment: A Narrative Review. *Biomedicines.* 2025 Jun 25;13(7):1554. doi: 10.3390/biomedicines13071554. PMID: 40722631; PMCID: PMC12293081.
194. Ferraresi A, Ghezzi I, Salwa A, Lualdi C, Dhanasekaran DN, Isidoro C. P53-Induced Autophagy Degradation of NKX3-2 Improves Ovarian Cancer Prognosis. *Cells.* 2025; 14(11):765. <https://doi.org/10.3390/cells14110765>.
193. Bonetto V, Ferraresi A, Sampò S, Isidoro C. Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders. *Int J Mol Sci.* 2025 May 16;26(10):4800. doi: 10.3390/ijms26104800.
192. Garavaglia B, Vallino L, Ferraresi A, Amoruso A, Pane M, Isidoro C. Probiotic-Derived Metabolites from *Lactiplantibacillus plantarum* OC01 Reprogram Tumor-Associated Macrophages to an Inflammatory Anti-Tumoral Phenotype: Impact on Colorectal Cancer Cell Proliferation and Migration. *Biomedicines.* 2025 Feb 3;13(2):339. doi: 10.3390/biomedicines13020339. PMID: 40002754; PMCID: PMC11853712.
191. Bellavite P, Donzelli A, Isidoro C. The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement. *J Clin Med.* 2024 Nov 30;13(23):7291. doi: 10.3390/jcm13237291. PMID: 39685749; PMCID: PMC11642405.
190. Beatrice Garavaglia, Letizia Vallino, Angela Amoruso, Marco Pane, Alessandra Ferraresi, Ciro Isidoro, The role of gut microbiota, immune system, and autophagy in the pathogenesis of inflammatory bowel disease: Molecular mechanisms and therapeutic approaches. *Aspects of Molecular Medicine, Volume 4, 2024, 100056,* <https://doi.org/10.1016/j.amolm.2024.100056>.

## Biographical sketch CIRO ISIDORO

189. Nadhan R, Isidoro C, Song YS, Dhanasekaran DN. LncRNAs and the cancer epigenome: Mechanisms and therapeutic potential. *Cancer Lett.* 2024 Nov 28;605:217297. doi: 10.1016/j.canlet.2024.217297. Epub 2024 Oct 16. PMID: 39424260.
188. Isidoro C, Ntanasis-Stathopoulos I. Editorial: Understanding patient nutrition and cancer progression. *Front Oncol.* 2024 Nov 25;14:1518083. doi: 10.3389/fonc.2024.1518083. PMID: 39655074; PMCID: PMC11625663.
187. Ferraresi A, Ghezzi I, Salwa A, Esposito A, Dhanasekaran DN, Isidoro C. NKX3-2 Induces Ovarian Cancer Cell Migration by HDAC6-Mediated Repositioning of Lysosomes and Inhibition of Autophagy. *Cells.* 2024 Nov 4;13(21):1816. doi: 10.3390/cells13211816. PMID: 39513923; PMCID: PMC11544992.
186. Salwa A, Ferraresi A, Vallino L, Maheshwari C, Moia R, Gaidano G, Isidoro C. High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias. *Int J Mol Sci.* 2024 Oct 27;25(21):11527. doi: 10.3390/ijms252111527. PMID: 39519080; PMCID: PMC11546612.
185. Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran DN, Isidoro C. Three-Dimensional In Vitro Cell Cultures as a Feasible and Promising Alternative to Two-Dimensional and Animal Models in Cancer Research. *Int J Biol Sci.* 2024 Sep 30;20(13):5293-5311. doi: 10.7150/ijbs.96469. PMID: 39430243; PMCID: PMC11488579.
184. Ferraresi A, Girone C, Maheshwari C, Vallino L, Dhanasekaran DN, Isidoro C. Ovarian Cancer Cell-Conditioning Medium Induces Cancer-Associated Fibroblast Phenoconversion through Glucose-Dependent Inhibition of Autophagy. *International Journal of Molecular Sciences.* 2024; 25(11):5691. <https://doi.org/10.3390/ijms25115691>
183. Ha JH, Radhakrishnan R, Nadhan R, Gomathinayagam R, Jayaraman M, Yan M, Kashyap S, Fung KM, Xu C, Bhattacharya R, Mukherjee P, Isidoro C, Song YS, Dhanasekaran DN. Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer. *Cancer Lett.* 2024 Apr 18:216891. doi: 10.1016/j.canlet.2024.216891. Epub ahead of print. PMID: 38642607.
182. Secomandi, E.; Esposito, A.; Camurani, G.; Vidoni, C.; Salwa, A.; Lualdi, C.; Vallino, L.; Ferraresi, A.; Isidoro, C. Differential Competitive Growth of Transgenic Subclones of Neuroblastoma Cells Expressing Different Levels of Cathepsin D Co-Cultured in 2D and 3D in Response to EGF: Implications in Tumor Heterogeneity and Metastasis. *Cancers* **2024**, *16*, 1343. <https://doi.org/10.3390/cancers16071343>
181. Sillapachaiyaporn C, Wongwan C, Mongkolpobsin K, Nilkhet S, Isidoro C, Chuchawankul S, Tencomnao T. Ergosterol promotes neurite outgrowth, inhibits amyloid-beta synthesis, and extends longevity: In vitro neuroblastoma and in vivo *Caenorhabditis elegans* evidence. *Life Sci.* 2024 Apr 2:122606. doi: 10.1016/j.lfs.2024.122606. Epub ahead of print. PMID: 38574884.
180. Ferraresi A, Thongchot S, Isidoro C. Resveratrol Promotes Self-digestion to Put Cancer to Sleep. *J Cancer Prev.* 2024 Mar 30;29(1):1-5. doi: 10.15430/JCP.24.001. Epub 2024 Mar 29. PMID: 38567110; PMCID: PMC10982519.
179. Chen X, Tsvetkov AS, Shen HM, Isidoro C, Ktistakis NT, Linkermann A, Koopman WJH, Simon HU, Galluzzi L, Luo S, Xu D, Gu W, Peulen O, Cai Q, Rubinsztein DC, Chi JT, Zhang DD, Li C, Toyokuni S, Liu J, Roh JL, Dai E, Juhasz G, Liu W, Zhang J, Yang M, Liu J, Zhu LQ, Zou W, Piacentini M, Ding WX, Yue Z, Xie Y, Petersen M, Gewirtz DA, Mandell MA, Chu CT, Sinha D, Eftekharpour E, Zhivotovsky B, Besteiro S, Gabrilovich DI, Kim DH, Kagan VE, Bayir H, Chen GC, Ayton S, Lünemann JD, Komatsu M, Krautwald S, Loos B, Baehrecke EH, Wang J, Lane JD, Sadoshima J, Yang WS, Gao M, Münz C, Thumm M, Kampmann M, Yu D, Lipinski MM, Jones JW, Jiang X, Zeh HJ, Kang R, Klionsky DJ, Kroemer G, Tang D. International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis. *Autophagy.* 2024 Mar 5. doi: 10.1080/15548627.2024.2319901. Epub ahead of print. PMID: 38442890.

## Biographical sketch CIRO ISIDORO

178. Thongchot S, Ferraresi A, Vidoni C, Salwa A, Vallino L, Kittirat Y, Loilome W, Namwat N, Isidoro C. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis. *Cancer Lett.* 2024 Feb 1;582:216589. doi: 10.1016/j.canlet.2023.216589. Epub 2023 Dec 12. PMID: 38097133.